Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand (vol 14, pg 531, 2023)

被引：0
|
作者：
Deerochanawong, Chaicharn [1 ]
Krittayaphong, Rungroj [2 ]
Romano, Jack Garcia Uranga [3 ]
Rhee, Nicolai A. [4 ]
Permsuwan, Unchalee [5 ,6 ]
机构：
[1] Rangsit Univ, Rajavithi Hosp, Coll Med, Minist Publ Hlth, Bangkok 10400, Thailand
[2] Mahidol Univ, Dept Med, Div Cardiol, Fac Med,Siriraj Hosp, Bangkok, Thailand
[3] Novo Nordisk, Dubai, U Arab Emirates
[4] Novo Nordisk, Bangkok, Thailand
[5] Chiang Mai Univ, Fac Pharm, CM HTA, Dept Pharmaceut Care, Chiang Mai 50200, Thailand
[6] Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Care, 239 Huaykaew Rd, Chiang Mai 50200, Thailand
来源：
DIABETES THERAPY | 2023年 / 14卷 / 05期
关键词：
D O I：
10.1007/s13300-023-01392-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：947 / 949
页数：3
相关论文
共 50 条
  • [1] Cost-Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
    Deerochanawong, Chaicharn
    Krittayaphong, Rungroj
    Romano, Jack Garcia Uranga
    Rhee, Nicolai R.
    Permsuwan, Unchalee
    DIABETES THERAPY, 2023, 14 (03) : 531 - 552
  • [2] Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
    Chaicharn Deerochanawong
    Rungroj Krittayaphong
    Jack Garcia Uranga Romano
    Nicolai A. Rhee
    Unchalee Permsuwan
    Diabetes Therapy, 2023, 14 : 531 - 552
  • [3] Correction to: Cost–Utility of Liraglutide Plus Standard of Care Versus Standard of Care in People with Type 2 Diabetes and Cardiovascular Risk in Thailand
    Chaicharn Deerochanawong
    Rungroj Krittayaphong
    Jack Garcia Uranga Romano
    Nicolai A. Rhee
    Unchalee Permsuwan
    Diabetes Therapy, 2023, 14 : 947 - 949
  • [4] Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
    Deerochanawong, Chaicharn
    Vareesangthip, Kriengsak
    Piyayotai, Dilok
    Thongsuk, Dittaya
    Pojchaijongdee, Nuch
    Permsuwan, Unchalee
    DIABETES THERAPY, 2021, 12 (07) : 1947 - 1963
  • [5] COST-UTILITY OF LURASIDONE VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH SCHIZOPHRENIA IN ITALY
    Bini, C.
    Marcellusi, A.
    Rotundo, M.
    D'ambrosio, F.
    Mennini, F. S.
    VALUE IN HEALTH, 2019, 22 : S686 - S686
  • [6] COST-UTILITY OF DALBAVANCIN VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH ABSSSI IN ITALY
    Rotundo, M.
    Bini, C.
    Marcellusi, A.
    Mennini, F. S.
    VALUE IN HEALTH, 2019, 22 : S599 - S599
  • [7] Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland
    Stawowczyk, Ewa
    Kawalec, Pawel
    Pilc, Andrzej
    PHARMACOTHERAPY, 2016, 36 (05): : 472 - 481
  • [8] Cost-Utility Analysis of Dapagliflozin as an Add-on to Standard of Care for Patients with Chronic Kidney Disease in Thailand
    Vareesangthip, Kriengsak
    Deerochanawong, Chaicharn
    Thongsuk, Dittaya
    Pojchaijongdee, Nuch
    Permsuwan, Unchalee
    ADVANCES IN THERAPY, 2022, 39 (03) : 1279 - 1292
  • [9] Automated Insulin Delivery Versus Standard of Care in the Management of People Living with Type 1 Diabetes and HbA1c <8%: A Cost-Utility Analysis in The Netherlands
    Serne, Erik H.
    Buompensiere, Maria Ida
    de Portu, Simona
    Smith-Palmer, Jayne
    Pohlmann, Johannes
    Cohen, Ohad
    DIABETES TECHNOLOGY & THERAPEUTICS, 2025,
  • [10] THE COST-UTILITY OF INSULIN DEGLUDEC COMPARED WITH CURRENT STANDARD OF CARE IN THE MANAGEMENT OF TYPE ONE AND TYPE TWO DIABETES MELLITUS IN BELGIUM
    Jugrin, A., V
    Lamotte, M.
    Malfait, M.
    Vandebrouck, T.
    VALUE IN HEALTH, 2013, 16 (07) : A442 - A443
12345